程序性死亡受体1抑制剂及白蛋白紫杉醇联合或不联合铂类对晚期转移或复发性宫颈癌的疗效比较  

Comparison of the efficacy and safety of programmed cell death protein 1 inhibitors combined with albumin-paclitaxel with or without platinum in the treatment of advanced metastasis or recurrent cervical cancer

作　　者：沈静 徐晶晶[1] 吕萌萌[1] 吴东辰 王金华[1,3] SHEN Jing;XU Jingjing;LYU Mengmeng;WU Dongchen;WANG Jinhua(Department of Gynecology oncology,The Affiliated Cancer Hospital of Nanjing Medical University,Nanjing,Jiangsu 210009,China;不详)

机构地区：[1]南京医科大学附属肿瘤医院妇瘤科,江苏南京210009 [2]东南大学附属中大医院江北院区,江苏南京210044 [3]西宁市第一人民医院妇科,青海西宁810000

出　　处：《中国临床研究》2024年第5期756-759,共4页Chinese Journal of Clinical Research

摘　　要：目的对比程序性死亡受体1(PD-1)抑制剂联合白蛋白紫杉醇方案、PD-1抑制剂联合白蛋白紫杉醇+铂类方案治疗晚期转移或复发性宫颈癌的有效性和安全性。方法回顾性分析2018年9月至2022年12月南京医科大学附属肿瘤医院接受PD-1抑制剂+白蛋白紫杉醇+铂类(A组)或PD-1抑制剂+白蛋白紫杉醇(B组)二线以上治疗晚期转移或复发性宫颈癌患者的临床资料,比较两组的客观缓解率(ORR)、无进展生存期(PFS),以及不良反应发生情况。结果共收集54例患者,其中A组37例,B组17例,中位年龄53岁,平均随访时间10个月。其中鳞状细胞癌45例,腺癌6例,腺鳞癌1例及神经内分泌小细胞癌2例。A组和B组ORR比较差异无统计学意义(35.30%vs 35.14%,P>0.05)。A组和B组PFS差异无统计学意义(11.7个月vs 7.3个月,P>0.05)。两组不良反应发生率、3级及以上不良反应发生率、免疫相关不良反应发生率差异均无统计学意义(P>0.05)。结论PD-1抑制剂+白蛋白紫杉醇+铂类对比PD-1抑制剂+白蛋白紫杉醇方案在晚期转移及复发性宫颈癌的二线以上治疗中并未增加疗效。Objective To compare the efficacy and safety of programmed cell death protein 1(PD-1)inhibitor+albumin-paclitaxel and platinum+PD-1 inhibitor+albumin-paclitaxel in the treatment of advanced metastasis or recurrent cervical cancer.Methods The clinical data of patients who had advanced metastatic or recurrent cervical cancer were treated with PD-1 inhibitor+albumin paclitaxel+platinum(group A)or anti-PD-1+albumin-bound paclitaxel(group B)in more than second-line therapy in the Affiliated Cancer Hospital of Nanjing Medical University from September 2018 to December 2022 were retrospectively analyzed.The objective response rate(ORR),progression-free survival(PFS)and the incidence of adverse reactions between the two groups were compared.Results A total of 54 patients were collected,37 in group A and 17 in group B.The median age was 53 years old,and the average follow-up time was 10 months.Among the patients,45 cases were squamous cell carcinoma,6 cases were adenocarcinoma,1 case was adenosquamous carcinoma,and 2 cases were neuroendocrine small cell carcinoma.There was no statistically significant difference in the ORR between group A and group B(35.30%vs 35.14%,P>0.05).There was no statistical significant difference in PFS between group A and group B(11.7 month vs 7.3 month,P>0.05).The differences in the incidence of adverse reactions,the incidence of adverse reactions with grade 3 and above,and the incidence of immune-related adverse reactions between the two groups were not statistically significant(P>0.05).Conclusion The PD-1 inhibitor+albumin paclitaxel+platinum regimen does not increase the efficacy compared with the PD-1 inhibitor+albumin paclitaxel regimen in more than second-line therapy of advanced metastatic and recurrent cervical cancer.

关 键 词：宫颈癌 晚期 白蛋白紫杉醇 程序性死亡受体1 程序性死亡受体1抑制剂 客观缓解率 无进展生存期 

分 类 号：R737.33[医药卫生—肿瘤] R743.3[医药卫生—临床医学]